The details of the immunogen for this antibody are not available.
This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Flow Cyt: Use 0.3µg for 106 cells.
IP: Use at an assay dependent dilution.
Inhibition of IL-2 or mitogen-induced T cell proliferation: Use at an assay dependent dilution.
In vitro blocking of IL-2 binding: Use at an assay dependent dilution.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Receptor for interleukin-2.
Involvement in disease
Genetic variations in IL2RA are associated with susceptibility to diabetes mellitus insulin-dependent type 10 (IDDM10) [MIM:601942]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
References for Anti-IL2 Receptor alpha antibody [3C7] (PE/Cy7 ®) (ab25393)
This product has been referenced in:
Lorenzo F et al. Structure-function study of the p55 subunit of murine IL-2 receptor by epitope mapping. J Immunol147:2970-7 (1991).
Read more (PubMed: 1717581) »
Moreau JL et al. Monoclonal antibodies identify three epitope clusters on the mouse p55 subunit of the interleukin 2 receptor: relationship to the interleukin 2-binding site. Eur J Immunol17:929-35 (1987).
Read more (PubMed: 2440696) »